by Eric Christianson | Apr 29, 2026 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Clonidine and guanfacine are both alpha-2 adrenergic agonists used in the treatment of ADHD, but they behave differently enough in clinical practice that they are not truly interchangeable. In this article, we will compare and contrast clonidine versus guanfacine in...
by Eric Christianson | Apr 19, 2026 | Respiratory Medication and Disease State Clinical Pearls
Beta-blockers have long been approached with caution in patients with asthma due to their potential to provoke bronchospasm and blunt the effects of rescue inhalers. This risk is largely driven by receptor selectivity. In this article, we will break down the best and...
by Eric Christianson | Apr 15, 2026 | Hematology and Immunology Medication and Disease State Clinical Pearls
Epoetin alfa (Epogen/Procrit) is a medication pharmacists commonly encounter in long-term care, dialysis, and oncology settings. While its role in stimulating red blood cell production seems straightforward, there are several key clinical pearls that are essential to...
by Eric Christianson | Apr 1, 2026 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
SSRIs are the drug of choice for many conditions. That is true of both obsessive-compulsive disorder and depression (excellent board exam nugget to remember). As you are reviewing a patient’s medication list or potentially helping with that patient’s...
by Eric Christianson | Mar 11, 2026 | Gastrointestinal Medication and Disease State Clinical Pearls
Folic acid, or vitamin B9, is an essential nutrient that is needed for cell growth and division, DNA formation, and red blood cell production. Certain medications can interfere with folate absorption and metabolism, which can lead to folate deficiency. Knowing which...
by Eric Christianson | Mar 8, 2026 | Endocrine Medication and Disease State Clinical Pearls
Diabetes management can be quite complex as it is a progressive disease, and goals can change depending on a variety of patient factors. In general, the ADA suggests an A1C goal of <7%, but in some cases, less stringent goals like <8% may be appropriate. The...
